References with Clinical Peptides

Clinical Peptides in Research

Clinical peptides play a vital role in immunotherapy, disease treatment, and regenerative medicine. JPT’s high-quality clinical peptides support groundbreaking research in autoimmune diseases, infectious diseases, and cancer immunotherapy. Below, you will find key studies referencing JPT’s clinical peptides in recent research.

References with Clinical Peptides

2022 - 2026

Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trialHuff et al., Nature Communications (2026) - PMID: 41667470

A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trialBaretti et al., Nature Medicine (2025) - PMID: 41286513

A small CEACAM5 peptide restores the protective function of CD8+ regulatory T cells in Crohn’s diseaseDunkin et al., Gastroenterology (2022) - PMID: 35700774

Rapid single-cell identification of EpsteinBarr virus-specific T-cell receptors for cellular therapyLammoglia Cobo et al., Cytotherapy (2022) - 35525797

Reconstitution of EBV-directed T cell immunity by adoptive transfer of peptide-stimulated T cells in a patient after allogeneic stem cell transplantation for AITLLammoglia Cobo et al., PLoS Pathogens (2022) - PMID: 35452490

2021

Designing Personalized Antigen-Specific Immunotherapies for Autoimmune Diseases—The Case for Using Ignored Target Cell Antigen DeterminantsTian et al., Cells (2022)

Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapyBasar et al., Cell Reports (2021)

Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS post-allogeneic transplantLulla et al., Blood (2021)

Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine 2 Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-ControlledPittisuttihum et al., MedRxiv (2021)

Combined PD-L1 and TIM-3 blockade improves the expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapyLak et al., MedRxiv (2021)

T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical EffectsVasileiou et al., Journal of Clinical Oncology (2021) - PMID : 33507803

Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFsWeingarten-Gabbay et al., Cell (2021) - PMID: 34171305

Archive

Preclinical Development and Clinical-Scale Manufacturing of HIV Gag-Specific, Lentivirus Modified CD4 T Cells for HIV Functional CureLi et al., Molecular Therapy (2020)

Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infectionsVasileiou et al., Haematologica (2020) - PMID: 31004020

Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipientsNelson et al., Blood Advances (2020)

The effects of β1 and β1+2 adrenergic receptor blockade on the exercise-induced mobilization and ex vivo expansion of virus-specific T cells: implications for cellular therapy and the anti-viral immune effects of exerciseKunz et al., Cell Stress and Chaperones (2020) - PMID: 32779001

HIV-Specific T Cells Can Be Generated against Non-escaped T Cell Epitopes with a GMP-Compliant Manufacturing PlatformPatel et al., Molecular Therapy: Methods & Clinical Developement (2020)

Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in high-risk melanoma patientsPavlick et al., Cancer Immunology Research (2020) - PMID : 31699709

Profiling HPV-16–specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patientsBhatt et al. Journal of Experimental Medicine (2020) - PMID: 32716518

An unbiased approach to defining bona fide cancer neoepitopes that elicit immune-mediated cancer rejectionBrennick et al., Journal of Clinical Investigation (2020)

Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiformeSmith et al., Journal of Clinical Investigation (2020)

Peptide Pools For Target Antigen Identification, Immune Monitoring, and Cellular TherapyA.Castro et al., Cytotherapy (2020) - PMID: n.a.

“Mini” bank of only 8 donors supplies CMV-directed T cells to diverse recipientsTzannou et al., Blood Advances (2019) - PMID : 31481503

T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapyKeller et al., British Journal of Haematology (2019) - PMID: 31219185

A non-functional neoepitope specific CD8+ T-cell response induced by tumor derived antigen exposure in vivoVormehr et al., Oncoimmunology (2019)

Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant patients: A single-arm open-label phase I clinical trialSmith et al., Clinical Trial (2019) - PMID: 29982441

HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and EfficacySung et al., Molecular Therapy (2018)

Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytesRamos et al., Journal of Clinical Investigation (2017) - PMID: 28805662

Autologous Adoptive T-Cell Therapy for Recurrent or Drug-Resistant Cytomegalovirus Complications in Solid Organ Transplant Patients: A Single-Arm Open-Label Phase I Clinical TrialSmith et al., Infectious Diseases Society of America (2016) - PMID: 29982441

Human Parainfluenza Virus-3 Can be Targeted by Rapidly Ex Vivo Expanded T LymphocytesMcLaughlin et al., Cytotherapy (2016) - PMID: 27692559

Peptide‐Stimulated Expansion of Virus‐Specific T Cells for Preventative Treatment After Allogeneic Stem Cell TransplantationGary et al., AppNote (2015) - PMID: n.a.

Broadly-Specific Cytotoxic T Cells Targeting Multiple HIV Antigens Are Expanded From HIV+ Patients: Implications for ImmunotherapyLam et al., Molecular Therapy (2015) - PMID: 25366030

Expanded Cytotoxic T-Cell Lymphocytes Target the Latent HIV ReservoirSung et al., Journal of Infectious Diseases (2015) - PMID: 25589335

Ex vivo Expansion of Human T cells for Adoptive Immunotherapy Using the Novel Xeno-free CTS Immune Cell Serum ReplacementSmith et al., Clinical & Translational Immunology (2015) - PMID: 25671129

PepMixes to Generate Multiviral CTLS with Broad SpecificityLeen et al., US Patent 20,150,010,519 (2015)

Complete Remission Following Decitabine/Dendritic Cell Vaccine for Relapsed NeuroblastomaKrishnadas et al., Pediatrics. (2013) - PMID: 23266925

QIMR Berghofer Medical Research Institute Selects JPT’s GxP PepMix™ Peptide Pool Technology to Support its Phase I/II Clinical Trials of Adoptive Immunotherapy for Human Cytomegalovirus-associated DiseasesPress Release (2014)

Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections After HSCTPapadopoulou et al., Sci Transl Med. (2014) - PMID: 24964991

Immunotherapeutic Strategies to Prevent and Treat Human Herpesvirus 6 Reactivation after Allogeneic Stem Cell TransplantationGerdemann et al. (2013) - PMID: 23152545

Rapidly Generated Multivirus-specific Cytotoxic T lymphocytes for the Prophylaxis and Treatment of Viral InfectionsGerdemann et al., Mol Ther. (2012) - PMID: 22801446

LMP-Specific T-Cells for Patients With Relapsed EBV-Positive Lymphoma (ALCI)Bollard et al. (2012) - PMID: n.a

Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative LymphomaGerdemann et al., Molecular Therapy (2011) - PMID: 21915103

Cytotoxic T Lymphocyte Therapy with Donor T Cells Prevents and Treats Adenovirus and Epstein-Barr Virus Infections after Haploidentical and Matched Unrelated Stem Cell TransplantationLeen et al., Blood (2009) - PMID: 19700662